Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara
Brii steps into neuroscience
Cross-border biotech Brii Biosciences said it will begin developing neuroscience programs as its second therapeutic area of interest, adding to its original focus on infectious diseases. The Beijing, China, and Durham, N.C.-based company has hired John Kraus as SVP of its neurosciences therapy area to lead the push. A veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Kraus was most recently VP of drug development services at CRO Icon plc (NASDAQ:ICLR).
Immunomedics resubmits ADC to regulators
Immunomedics Inc. (NASDAQ:IMMU) has resubmitted a BLA for sacituzumab govitecan to FDA seeking the antibody-drug conjugate's accelerated approval to treat metastatic triple-negative breast cancer in a third-line setting. The company received a complete response letter for the therapy from FDA in January. Sacituzumab is a mAb against TROP2 conjugated with SN-38, the active metabolite of irinotecan. Immunomedics also proposed a $250 million stock offering after market hours Tuesday (see "Delay For Immunomedics' ADC")...